Number 688 • May 2017

Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Teva-Spironolactone 25 mg Tablet (DIN 00613215) manufactured by Teva Canada Limited, Aldactone 25 mg Tablet (DIN 00028606) manufactured by Pfizer Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Teva Canada Limited has advised Alberta Blue Cross that the shortage of Teva-Spironolactone 25 mg Tablet (DIN 00613215) has been resolved.

As a result, Aldactone 25 mg Tablet (DIN 00028606) will no longer be considered a temporary benefit for the ADBL after June 1, 2017.

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Doxepin 25 mg Capsule (DIN 02050005) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 5, 2017.**

DOXEPIN HCL

25 MG CAPSULE

00002050005	APO-DOXEPIN	APX	\$ 0.2940
00000024333	SINEQUAN	APR	\$ 0.3266

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**



